Physician profile
Michael Siedlecki
NPI 1205811361
$4,099.83
in general payments reported to CMS, 2019-2025
13 companies · $287 in 2025
The $287 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,193 · 2020: $459 · 2021: $462 · 2022: $594 · 2023: $600 · 2024: $506 · 2025: $287.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,367 · Education: $24.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,367.12 |
| Education | $24.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,380.52 | 2019-2024 | Farxiga |
| Janssen Pharmaceuticals, INC | $717.79 | 2019-2022 | |
| Fresenius USA Marketing, INC. | $432.38 | 2019-2023 | Velphoro |
| Bayer Healthcare Pharmaceuticals INC. | $386.94 | 2022-2025 | |
| Mallinckrodt Hospital Products INC. | $292.42 | 2024-2025 | Terlivaz |
| Amarin Pharma, INC. | $223.60 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $124.04 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $121.91 | 2020 | |
| Aurinia Pharma U.S., INC. | $111.25 | 2024 | Lupkynis |
| Amgen INC. | $97.05 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $95.33 | 2024 | Jardiance |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $91.99 | 2019 | |
| Akebia Therapeutics INC | $24.61 | 2024 | Vafseo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Siedlecki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.